Art

J-GLOBAL ID：201802234897494699   Reference number：18A2243094

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib

扁平上皮癌に形質転換したEGFR変異肺腺癌はアファチニブに対して持続効果を示す

Author (9)： Sato Mitsuo (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan) ,  Matsui Akira (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan) ,  Shimoyama Yoshie (Department of Pathology, Nagoya University Graduate School of Medicine, Japan) ,  Omote Norihito (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan) ,  Morise Masahiro (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan) ,  Hase Tetsunari (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan) ,  Tanaka Ichidai (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan) ,  Suzuki Kojiro (Department of Radiology, Nagoya University Graduate School of Medicine, Japan) ,  Hasegawa Yoshinori (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 57  Issue： 23  Page： 3429-3432(J-STAGE)  Publication year： 2018 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： EGFR gene ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2243094&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (4)： erlotinib ,  afatinib ,  EGFR mutation ,  squamous cell carcinoma transformation

JST classification (2)： Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (3)： BIBW2992 ,  Erlotinib ,  Pemetrexed

Reference (17)：

• 1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
• 2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
• 3. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26, 2011.
• 4. Scher KS, Saldivar JS, Fishbein M, Marchevsky A, Reckamp KL. EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. J Natl Compr Canc Netw 11: 1040-1044, 2013.
• 5. Hsieh MS, Jhuang JY, Hua SF, Chou YH. Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment. Ann Thorac Surg 99: 316-319, 2015.

Terms in the title (7)： 扁平上皮癌 ,  形質転換 ,  EGFR ,  変異 ,  肺腺癌 ,  アファチニブ ,  持続効果